Leerink Partners Downgrades AN2 Therapeutics (ANTX) to Market Perform
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz downgraded AN2 Therapeutics (NASDAQ: ANTX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
